A Canadian clinical trial led by researchers at the University of Calgary’s Hotchkiss Brain Institute (HBI), at the Cumming School of Medicine (CSM), shows that minocycline, a common acne medication, can slow the progress of relapsing-remitting multiple sclerosis (MS) in people who have recently experienced their first symptoms. In addition to being an unexpected discovery – an acne drug benefitting a neurological disorder – the discovery is significant as it offers a safe and affordable treatment option for those with early onset MS.
You are hereNews & Events
By using advanced, highly-sensitive magnetic resonance imaging (MRI) techniques, Dr. Rauscher and his team are hoping to better understand how damage occurs and how MRI can be used to monitor if new therapies are protective or have the potential to repair.
The study presents novel information because no work so far has presented an extensive risk profile of the beta-interferons in the real-world setting.
Study suggests possibility of MS prodrome, with increased health service use five years before the first demyelinating event.
As information-sharing has become decentralized in our digital age, are traditional approaches to science communication selling research short? A new editorial from Dr. Julie Robillard suggests that new challenges in communicating research discoveries are an opportunity for researchers to take greater initiative in sharing their work with the public, especially online.
“Right now, there is exciting and growing evidence to suggest that the microbiota are associated with some diseases of the brain. However, more work is still needed.” says Dr. Tremlett. “One real challenge will be to prove a causative link.”
According to new research from Dr. Jacqueline Quandt, published recently in Brain, Behaviour and Immunity, a simple compound shows promise in altering immune responses without eliminating cells and in doing so protects the cells in the nervous system and prevents the underlying neurodegeneration in models of MS.
A new physician-engagement initiative is coming to UBC Hospital and the Djavad Mowafaghian Centre for Brain Health.
The initiative’s goal is to involve physicians working in acute care facilities as true partners in the healthcare decision-making process, and help generate improvements that will make our future BC healthcare system sustainable. Without involving physicians, achieving better patient care, and better community health at the lowest cost possible will remain elusive goals.
On the first floor of the Djavad Mowafaghian Centre for Brain Health, a massive, two decade-long project has been quietly underway for the past three years. The Vancouver Data Collection Site for the Canadian Longitudinal Study on Aging (CLSA) is based here, and Dr. Heather Stewart and her team are returning to the Centre to start the first follow-up after 18 months collecting data at SFU Surrey’s CLSA data collection site.